Physician profile
Ramsay S Farah
NPI 1770597858
$4,856.77
in general payments reported to CMS, 2019-2025
26 companies · $922 in 2025
The $922 reported for 2025 was more than what a typical Dermatopathology (Dermatology) provider received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $843 · 2020: $206 · 2021: $254 · 2022: $427 · 2023: $1,086 · 2024: $1,119 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,929 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,928.95 |
| Education | $198.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $895.78 | 2019-2025 | Tremfya, Stelara, Remicade |
| E.R. Squibb & Sons, L.L.C. | $511.20 | 2022-2025 | Sotyktu |
| Abbvie INC. | $497.75 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $450.75 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $428.70 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $327.72 | 2023-2025 | Opzelura |
| Galderma Laboratories, L.P. | $306.81 | 2024-2025 | Nemluvio, Aklief |
| Pfizer INC. | $219.11 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $202.88 | 2019-2025 | Ilumya |
| Kyowa Kirin, INC. | $157.06 | 2019-2020 | |
| Amgen INC. | $147.05 | 2019-2025 | Otezla |
| Novartis Pharmaceuticals Corporation | $121.10 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.07 | 2023-2025 | Spevigo |
| Leo Pharma INC. | $115.11 | 2019-2024 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $81.69 | 2022-2025 | Siliq, Duobrii, Targretin |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $65.64 | 2024-2025 | Bimzelx |
| Prugen, INC. Pharmaceuticals | $41.64 | 2019 | |
| Sensus Healthcare, INC. | $34.13 | 2024 | |
| Celgene Corporation | $24.19 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $23.28 | 2019 | |
| Kerecis Limited | $17.88 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Biofrontera INC. | $16.74 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Merck Sharp & Dohme LLC | $15.43 | 2019 | |
| Vyne Pharmaceuticals INC. | $13.05 | 2020 | |
| Genentech USA, INC. | $12.60 | 2019 | |
| Stemline Therapeutics INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramsay Farah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.